Welcome to our dedicated page for Artivion SEC filings (Ticker: AORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Artivion, Inc. (NYSE: AORT), a medical device company focused on cardiac and vascular surgery and the treatment of aortic diseases. Through these filings, investors can review Artivion’s detailed financial statements, risk disclosures, material agreements and governance information.
Artivion’s periodic reports on Forms 10-K and 10-Q describe its business, which includes aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues, as well as preservation services for cardiac and vascular tissues. These filings outline segment-level information, geographic reach and key risk factors associated with its aortic-focused product portfolio and international operations.
Current reports on Form 8-K document material events such as quarterly financial results, amendments to the company’s credit and guaranty agreement, real estate purchase contracts for manufacturing and office facilities, and executive leadership changes. For example, recent 8-K filings discuss an amendment that extended the maturity of term loan and revolving credit facilities and added a secured delayed draw term loan facility, as well as agreements to purchase properties supporting On-X manufacturing operations in Austin, Texas.
On Stock Titan, Artivion’s SEC filings are updated in near real time as they are posted to EDGAR. AI-powered summaries help explain complex sections of lengthy documents, such as credit agreement amendments, non-GAAP reconciliations, and detailed risk factor discussions. Investors can quickly locate annual reports (Form 10-K), quarterly reports (Form 10-Q), and current reports (Form 8-K), and use AI-generated highlights to understand how new filings may relate to Artivion’s aortic device portfolio, clinical programs, capital structure and corporate strategy.
Artivion, Inc. is asking stockholders to vote at its virtual-only 2026 Annual Meeting on May 12, 2026 at 9:00 a.m. ET. Holders of common stock as of March 16, 2026 may vote on electing nine directors, approving executive pay on an advisory basis, and ratifying Ernst & Young LLP as independent auditor for 2026.
The Board states all non-employee directors are independent under NYSE rules and recommends voting FOR all director nominees, FOR the advisory “Say on Pay” resolution, and FOR auditor ratification. The proxy also describes virtual participation, quorum and voting standards, director compensation, board committee structure, and Artivion’s corporate governance and sustainability practices.
Artivion Inc received Amendment No. 6 to a Schedule 13G/A from The Vanguard Group that reports zero shares beneficially owned of Common Stock and 0% of the class. The filing reflects an internal realignment on January 12, 2026 under SEC Release No. 34-39538, after which certain Vanguard subsidiaries will report holdings separately. The filing lists Vanguard's Malvern, PA address and states that no single other person holds more than 5% of the class. The form is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
ARTIVION, INC. VP and Chief Accounting Officer Amy Horton reported both a stock award and a small share sale. She received 7,475 shares of common stock on March 2, 2026 as part of a performance stock unit grant made on February 28, 2025, with additional portions scheduled to vest in 2027 and 2028 if she remains employed on those dates. On March 3, 2026, 901 shares were sold at an average price of $37.7756 to cover tax withholding obligations arising from the vesting of performance stock units, and this "sell to cover" was described as non-discretionary. After the sale, she directly held 139,088 shares of common stock.
ARTIVION, INC. executive Jean F. Holloway, SVP and General Counsel, reported equity compensation activity and related tax sales in company stock. She acquired 27,795 shares of common stock on a grant or award basis at $0.00 per share, tied to performance stock units granted in February 2025, with remaining portions scheduled to vest in February 2027 and February 2028 subject to continued employment. Following this vesting, she sold 3,843 shares at an average price of $37.7756 on March 3, 2026 and 8,962 shares at $38.00 on March 4, 2026 solely to cover tax withholding obligations under a “sell to cover” arrangement, which the filing states is not a discretionary transaction. After these transactions, she directly owned 185,095 shares of Artivion common stock.
ARTIVION, INC. senior vice president Stanton Marshall S. reported two stock transactions involving company common shares. He acquired 21,838 shares on a grant/award basis at $0.0000 per share as part of performance stock units granted in February 2025. According to the award terms, additional portions of this grant are eligible to vest on February 28, 2027 and February 28, 2028, subject to continued employment on each vesting date. On March 3, 2026, 2,149 shares were sold at an average price of $37.7756 per share to cover tax withholding obligations through a sell-to-cover transaction, which the company notes was not a discretionary sale. After these transactions, Marshall directly owned 60,097 shares of Artivion common stock.
Artivion, Inc. Chief Commercial Officer John E. Davis reported two equity transactions in company common stock. On March 2, 2026, he acquired 28,845 shares at $0.00 per share, issued upon vesting of performance stock units from a February 2025 grant. On March 3, 2026, 4,573 shares were sold at an average price of $37.7756 per share to cover tax withholding obligations in a non-discretionary “sell to cover” transaction. Following these movements, Davis held 230,794 shares of Artivion common stock directly.
Artivion, Inc. executive Lance A. Berry reported equity compensation activity and a related tax sale of shares. He acquired 40,874 shares of common stock on a grant or award basis at a price of $0.0000 per share on March 2, 2026, connected to performance stock units granted on February 28, 2025. One third of these units were issued on March 2, 2026, with the remaining thirds scheduled to be eligible to vest on February 28, 2027 and February 28, 2028, assuming continued employment.
On March 3, 2026, 6,316 shares of common stock were sold in an open-market transaction at an average price of $37.7756 per share to cover tax withholding obligations arising from the vesting of these performance stock units. The filing states this “sell to cover” transaction was undertaken to satisfy tax obligations and does not represent a discretionary trade. Following these transactions, Berry directly held 210,827 shares of Artivion common stock.
Artivion, Inc. President & CEO James P. Mackin reported both an equity award and a related share sale. He acquired 116,948 shares of common stock on a grant/award basis at $0.00 per share following the vesting of performance stock units from a February 2025 grant.
On the next trading day, he sold 17,887 shares of common stock at an average price of $37.7756 per share in an open‑market transaction specifically to cover tax withholding obligations under a “sell to cover” arrangement, characterized as a non‑discretionary transaction. Following these transactions, he directly owned 947,275 shares of Artivion common stock.
Jean F Holloway reports proposed sales of common stock under Rule 144. The notice lists recent transactions including 03/02/2026 sale of 2,183 shares for $83,008.36, 02/24/2026 sale of 1,668 shares for $59,535.92, and 02/23/2026 sale of 3,079 shares for $115,733.45.